Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares RepurchasedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytek Biosciences (CTKB) Free Cash Flow (2020 - 2025)

Cytek Biosciences' Free Cash Flow history spans 6 years, with the latest figure at -$4.8 million for Q4 2025.

  • For Q4 2025, Free Cash Flow fell 348.57% year-over-year to -$4.8 million; the TTM value through Dec 2025 reached -$8.8 million, down 134.8%, while the annual FY2025 figure was -$8.8 million, 134.8% down from the prior year.
  • Free Cash Flow reached -$4.8 million in Q4 2025 per CTKB's latest filing, down from -$1.6 million in the prior quarter.
  • In the past five years, Free Cash Flow ranged from a high of $13.2 million in Q3 2024 to a low of -$10.2 million in Q2 2022.
  • Average Free Cash Flow over 5 years is -$14200.0, with a median of -$958000.0 recorded in 2025.
  • Peak YoY movement for Free Cash Flow: tumbled 730.59% in 2022, then skyrocketed 507.11% in 2023.
  • A 5-year view of Free Cash Flow shows it stood at $5.8 million in 2021, then plummeted by 134.18% to -$2.0 million in 2022, then surged by 507.11% to $8.0 million in 2023, then tumbled by 76.05% to $1.9 million in 2024, then tumbled by 348.57% to -$4.8 million in 2025.
  • Per Business Quant, the three most recent readings for CTKB's Free Cash Flow are -$4.8 million (Q4 2025), -$1.6 million (Q3 2025), and -$2.1 million (Q2 2025).